Your session is about to expire
What is Syndros
DronabinolThe Generic name of this drug
Treatment SummaryDronabinol (also known as Marinol) is a synthetic form of THC, the active ingredient in marijuana. It affects the body by binding to certain receptors, which can result in increased appetite, reduced pain, and altered cognitive processes. It is commonly prescribed to treat anorexia in people with AIDS and to help reduce nausea and vomiting caused by cancer treatments. It is also used to activate THC and CBD, which are two compounds found in marijuana that have medicinal properties. THC and CBD interact with receptors found throughout the body, and are believed to help with a wide range of medical conditions including inflammation, cardiovascular function, learning, pain
Dronabinolis the brand name
Syndros Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dronabinol
Dronabinol
1994
62
Effectiveness
How Syndros Affects PatientsDronabinol may cause an increased heart rate and redness around the eyes. Its effects on blood pressure vary, but some people have experienced lightheadedness when they stand up too quickly. It can also affect mood, thinking, memory, and senses, and these effects may become stronger with higher doses. After taking it orally, the drug usually takes effect within half an hour to an hour, with its peak effect between 2 to 4 hours. Its psychoactive effects can last for 4 to 6 hours, and its appetite stimulant effect may last for up to 24 hours. With long-term use, people may develop tolerance to its
How Syndros works in the bodyDronabinol is a synthetic version of the chemical found in cannabis (marijuana) that causes its psychological effects. This chemical, Delta-9-tetrahydrocannabinol (Δ⁹-THC), affects the body by activating specific receptors, called CB1R and CB2R, that cause changes in appetite, reduce pain and alter emotional and cognitive processes.
When to interrupt dosage
The proposed dosage of Syndros is contingent upon the diagnosed condition, including Unintentional Weight Loss, Pharmacotherapy and Acquired Immunodeficiency Syndrome. The extent of dosage is subject to the administration strategy (e.g. Buccal or Capsule - Oral) presented in the table below.Condition
Dosage
Administration
Acquired Immunodeficiency Syndrome
, 2.5 mg, 10.0 mg, 5.0 mg, 5.0 mg/mL, 2.7 mg/pump actuation
, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Spray - Buccal, Buccal, Spray, Solution, Solution - Oral
Obesity
, 2.5 mg, 10.0 mg, 5.0 mg, 5.0 mg/mL, 2.7 mg/pump actuation
, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Spray - Buccal, Buccal, Spray, Solution, Solution - Oral
Pharmacotherapy
, 2.5 mg, 10.0 mg, 5.0 mg, 5.0 mg/mL, 2.7 mg/pump actuation
, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Spray - Buccal, Buccal, Spray, Solution, Solution - Oral
inadequate response to conventional therapy
, 2.5 mg, 10.0 mg, 5.0 mg, 5.0 mg/mL, 2.7 mg/pump actuation
, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Spray - Buccal, Buccal, Spray, Solution, Solution - Oral
Loss of Appetite
, 2.5 mg, 10.0 mg, 5.0 mg, 5.0 mg/mL, 2.7 mg/pump actuation
, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Spray - Buccal, Buccal, Spray, Solution, Solution - Oral
Warnings
Syndros ContraindicationsCondition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Common Syndros Drug Interactions
Drug Name
Risk Level
Description
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Dronabinol.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Dronabinol.
Anagrelide
Major
The metabolism of Anagrelide can be decreased when combined with Dronabinol.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Dronabinol.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Dronabinol.
Syndros Toxicity & Overdose RiskSYNDROS, a synthetic cannabinoid with alcohol, may cause harm to a fetus. Pregnant women should not take SYNDROS. Although there is limited research on the effect of synthetic cannabinoids during pregnancy, using cannabis or alcohol during pregnancy has been known to cause negative outcomes for the baby. Breastfeeding mothers should also not take SYNDROS, as it can be passed to the baby and cause adverse reactions. SYNDROS has not been tested on children, and elderly patients may be more sensitive to its effects. Those taking SYNDROS may be at risk of addiction or experiencing psychosis, hallucinations, and paranoia
Syndros Novel Uses: Which Conditions Have a Clinical Trial Featuring Syndros?
137 active clinical trials are in progress to evaluate the potential of Syndros to provide Pharmacotherapy, counteract Unintentional Weight Loss and enhance response to conventional therapy.Condition
Clinical Trials
Trial Phases
Obesity
135 Actively Recruiting
Phase 2, Not Applicable, Phase 4, Phase 3, Phase 1, Early Phase 1
Loss of Appetite
3 Actively Recruiting
Phase 1, Phase 2, Not Applicable
inadequate response to conventional therapy
0 Actively Recruiting
Pharmacotherapy
1 Actively Recruiting
Phase 4
Acquired Immunodeficiency Syndrome
5 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable
Syndros Reviews: What are patients saying about Syndros?
4Patient Review
11/14/2018 This is an expensive but effective treatment for cancer patients undergoing chemotherapy. It alleviates both pain and nausea with minimal side effects.
Patient Q&A Section about syndros
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Syndros available?
"The FDA has recently approved Syndros, a liquid form of synthetic cannabinoid dronabinol, for the treatment of cachexia and nausea and vomiting in AIDS and cancer patients, with the potential as a pain management agent."
Answered by AI
What is the difference between Syndros and Marinol?
"Syndros is a liquid version of Marinol (dronabinol), which is a soft gel capsule that contains tetrahydrocannabinol (THC), the primary active compound in cannabis (marijuana). Marinol is developed by AbbVie Inc. Syndicate is the first and only FDA-approved dronabinol solution that is meant to be taken orally."
Answered by AI
What schedule drug is Syndros?
"The DEA has announced that it has scheduled the newly approved synthetic THC-containing drug, Syndros, as a Class II substance."
Answered by AI
Is Syndros FDA-approved?
"The first and only FDA-approved medication containing tetrahydrocannabinol (THC) is SYNDROS. It is a liquid cannabinoid that is used in adults to treat nausea and vomiting caused by chemotherapy, in people who have not experienced relief from conventional anti-nausea medication."
Answered by AI